Drug Profile
Research programme: liver disorder therapeutics - Xian Xingtong Pharmaceuticals Research
Latest Information Update: 17 Sep 2020
Price :
$50
*
At a glance
- Originator Chiva Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C; Liver cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-B in China
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-C in China
- 16 Jul 2016 No recent reports of development identified for research development in liver cancer in China